Literature DB >> 31558270

Incidence of, Associations With and Prognostic Impact of Worsening Renal Function in Heart Failure With Different Ejection Fraction Categories.

Ida Löfman1, Karolina Szummer2, Marie Evans3, Juan-Jesus Carrero4, Lars H Lund2, Tomas Jernberg5.   

Abstract

There are no studies of long-term worsening renal function (WRF) in heart failure (HF) with different ejection fraction (EF) groups. The aim was to compare incidence of, associations with and prognostic impact of WRF in HF with preserved (HFpEF), mid-range (HFmrEF), and reduced EF (HFrEF). The Swedish Heart Failure Registry (SwedeHF) was merged with the Stockholm Creatinine Measurement (SCREAM) registry 2006 to 2010. The associations between EF and WRF (≥25% decrease in eGFR) and the associations between WRF25-49% and WRF≥50% within year one and subsequent all-cause mortality were all assessed with multiadjusted Cox regression. Of 7,154 patients, 41.6% of HFpEF versus 34.5% and 35.4% of HFmrEF and HFrEF patients developed WRF≥25% during year one. The WRF risk was higher in HFpEF (reference) than in HFmrEF, hazard ratio (95% confidence interval) 0.890 (0.794 to 0.997) and HFrEF 0.870 (0.784 to 0.965). WRF within year one was strongly associated with subsequent long-term mortality in all EF groups, yielding adjusted HRs with WRF25-49% and WRF≥50%: HFpEF, 1.101 (0.913 to 1.328) and 2.096 (1.652 to 2.659), in HFmrEF 1.654 (1.353 to 2.022) and 2.375 (1.807 to 3.122) and in HFrEF 1.212 (1.060 to 1.386) and 1.694 (1.412 to 2.033). In conclusion, the long-term WRF risk was high in HF and highest in HFpEF. WRF was strongly associated with mortality in all EF groups, although in HFpEF only with the most severe WRF.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31558270     DOI: 10.1016/j.amjcard.2019.07.065

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Can fractional excretion of sodium predict worsening of renal function, in-hospital mortality, and length of hospital stay in acute decompensated heart failure?

Authors:  Farzaneh Ahmadi; Ekhlas Torfi; Sayed Mohammadreza Afshani; Saadat Kazemi-Mansourabad; Fatemeh Hayati
Journal:  ARYA Atheroscler       Date:  2021-11

2.  Phenomapping in patients experiencing worsening renal function during hospitalization for acute heart failure.

Authors:  Ryuichiro Yagi; Makoto Takei; Shun Kohsaka; Yasuyuki Shiraishi; Nobuhiro Ikemura; Satoshi Shoji; Nozomi Niimi; Satoshi Higuchi; Ayumi Goda; Takashi Kohno; Yuji Nagatomo; Yosuke Nishihata; Yasumori Sujino; Mike Saji; Yukinori Ikegami; Shintaro Nakano; Toshiyuki Takahashi; Keiichi Fukuda; Tsutomu Yoshikawa
Journal:  ESC Heart Fail       Date:  2021-09-20

3.  Percutaneous edge-to-edge mitral valve repair for mitral regurgitation improves heart failure symptoms in heart failure with preserved ejection fraction patients.

Authors:  Matthias Gröger; Jinny Karin Scheffler; Florian Schösser; Leonhard Moritz Schneider; Wolfgang Rottbauer; Sinisa Markovic; Mirjam Keßler
Journal:  ESC Heart Fail       Date:  2021-09-09

Review 4.  Heart failure with mid-range or mildly reduced ejection fraction.

Authors:  Gianluigi Savarese; Davide Stolfo; Gianfranco Sinagra; Lars H Lund
Journal:  Nat Rev Cardiol       Date:  2021-09-06       Impact factor: 32.419

Review 5.  Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?

Authors:  Paolo Severino; Andrea D'Amato; Silvia Prosperi; Alessandra Dei Cas; Anna Vittoria Mattioli; Antonio Cevese; Giuseppina Novo; Maria Prat; Roberto Pedrinelli; Riccardo Raddino; Sabina Gallina; Federico Schena; Corrado Poggesi; Pasquale Pagliaro; Massimo Mancone; Francesco Fedele
Journal:  J Clin Med       Date:  2022-02-06       Impact factor: 4.241

Review 6.  The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines.

Authors:  Matteo Beltrami; Massimo Milli; Lorenzo Lupo Dei; Alberto Palazzuoli
Journal:  J Clin Med       Date:  2022-04-17       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.